Drugs & Targets Novartis’s Kymriah becomes first gene therapy to get FDA approval September 01, 2017Vol.43 No.32
Drugs & Targets FDA approves Mylotarg for treatment of acute myeloid leukemia September 01, 2017Vol.43 No.32
Drugs & Targets FDA approves Lynparza (olaparib) tablets for maintenance treatment in ovarian cancer September 01, 2017Vol.43 No.32
NCI requests $591 million in additional funding for FY19 September 01, 2017Vol.43 No.32By Matthew Bin Han Ong
Drugs & Targets Ocugen gets Orphan Drug designation for ocular graft vs. host disease September 01, 2017Vol.43 No.32
Drugs & Targets FDA acts to remove unproven treatment used in ‘stem cell’ centers September 01, 2017Vol.43 No.32
Conversation with The Cancer Letter More than three million life-years added over 60 years as a result of SWOG clinical trials August 08, 2017Vol.43 No.31By Claire Dietz
Funding Opportunities NETRF announces grants for neuroendocrine cancer research August 04, 2017Vol.43 No.31
Drugs & Targets Enasidenib, companion diagnostic get FDA approval for relapsed or refractory AML August 04, 2017Vol.43 No.31
